Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities. - OpacWWW

Szczegóły
Abstrakt

Tytuł:: Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities.
Autorzy:: Alhouayek M; Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université catholique de Louvain, 1200 Bruxelles, Belgium. Electronic address: .
Ameraoui H; Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université catholique de Louvain, 1200 Bruxelles, Belgium.
Muccioli GG; Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Université catholique de Louvain, 1200 Bruxelles, Belgium. Electronic address: .
Źródło:: Biochimica et biophysica acta. Molecular and cell biology of lipids [Biochim Biophys Acta Mol Cell Biol Lipids] 2021 Feb; Vol. 1866 (2), pp. 158854. Date of Electronic Publication: 2020 Nov 04.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Amsterdam : Elsevier
MeSH Terms:: Colitis, Ulcerative/*immunology
Crohn Disease/*immunology
Gastrointestinal Agents/*pharmacology
Intestinal Mucosa/*pathology
Lipid Metabolism/*immunology
Adaptive Immunity/drug effects ; Animals ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/metabolism ; Colitis, Ulcerative/pathology ; Crohn Disease/drug therapy ; Crohn Disease/metabolism ; Crohn Disease/pathology ; Disease Models, Animal ; Drug Therapy, Combination/methods ; Endocannabinoids/immunology ; Endocannabinoids/metabolism ; Fatty Acids/immunology ; Fatty Acids/metabolism ; Gastrointestinal Agents/therapeutic use ; Humans ; Immunity, Innate/drug effects ; Inflammation/drug therapy ; Inflammation/immunology ; Inflammation/metabolism ; Inflammation/pathology ; Intestinal Mucosa/immunology ; Lipid Metabolism/drug effects ; Lysophospholipids/immunology ; Lysophospholipids/metabolism ; Oxysterols/immunology ; Oxysterols/metabolism ; Signal Transduction/drug effects ; Signal Transduction/immunology
Contributed Indexing:: Keywords: Autotaxin; Docosahexaenoic acid; Eicosanoids; Palmitoylethanolamide; SPM; Short chain fatty acids
Substance Nomenclature:: 0 (Anti-Inflammatory Agents)
0 (Endocannabinoids)
0 (Fatty Acids)
0 (Gastrointestinal Agents)
0 (Lysophospholipids)
0 (Oxysterols)
Entry Date(s):: Date Created: 20201106 Date Completed: 20210423 Latest Revision: 20210423
Update Code:: 20240105
DOI:: 10.1016/j.bbalip.2020.158854
PMID:: 33157277
: Czasopismo naukowe

Full Text Finder

Inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, are lifelong diseases that remain challenging to treat. IBDs are characterized by alterations in intestinal barrier function and dysregulation of the innate and adaptive immunity. An increasing number of lipids are found to be important regulators of inflammation and immunity as well as gut physiology. Therefore, the study of lipid mediators in IBDs is expected to improve our understanding of disease pathogenesis and lead to novel therapeutic opportunities. Here, through selected examples - such as fatty acids, specialized proresolving mediators, lysophospholipids, endocannabinoids, and oxysterols - we discuss how lipid signaling is involved in IBD physiopathology and how modulating lipid signaling pathways could affect IBDs.
(Copyright © 2020. Published by Elsevier B.V.)

Informacja

Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities.